Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 135
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Clin Radiol ; 64(9): 897-902, 2009 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-19664480

RESUMEN

AIM: To report a case series in which the radiological features of the subcutaneous use of calcium hydroxylapatite (CaHa) dermal fillers are described for the first time. MATERIALS AND METHODS: Five patients with facial hyperattenuating hypermetabolic subcutaneous lesions were identified on 2- [(18)F]-fluoro-2-deoxy-D-glucose (FDG) positron-emission tomography/computed tomography (PET/CT), who gave a history of facial injections to augment physical appearance. Correlation with additional imaging studies was performed. RESULTS: All cases had subcutaneous high attenuation material on CT (range 280-700HU), which was FDG avid on PET, with a standardized uptake value (SUV) range of 2.9-13.4. Magnetic resonance imaging (MRI) demonstrated a heterogeneous intermediate signal intensity subcutaneous lesion with enhancement post-gadolinium in one case. CONCLUSIONS: CaHa dermal filler is hyperattenuating on CT, hypermetabolic on FDG-PET imaging, of intermediate signal intensity on MRI, and is a potential cause of a false-positive imaging study.


Asunto(s)
Materiales Biocompatibles/uso terapéutico , Técnicas Cosméticas , Durapatita/uso terapéutico , Adulto , Anciano , Materiales Biocompatibles/farmacocinética , Durapatita/farmacocinética , Cara/diagnóstico por imagen , Reacciones Falso Positivas , Femenino , Fluorodesoxiglucosa F18 , Humanos , Inyecciones Subcutáneas , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Tomografía de Emisión de Positrones , Radiofármacos , Procedimientos de Cirugía Plástica , Estudios Retrospectivos , Tomografía Computarizada por Rayos X , Adulto Joven
2.
Br J Pharmacol ; 152(6): 870-9, 2007 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-17700726

RESUMEN

BACKGROUND AND PURPOSE: I(Kur) (Ultra-rapid delayed rectifier current) has microM sensitivity to 4-aminopyridine (4-AP) and is an important modulator of the plateau amplitude and action potential duration in canine atria. Kv1.5 encodes I(Kur) and is present in both atria and ventricles in canines and humans. We hypothesized that a similar plateau outward current with microM sensitivity to 4-AP is present in canine ventricle. EXPERIMENTAL APPROACH: We used established voltage clamp protocols and used 4-AP (50 and 100 microM) to measure a plateau outward current in normal canine myocytes isolated from the left ventricular mid-myocardium. KEY RESULTS: Action potential recordings in the presence of 4-AP showed significant prolongation of action potential duration at 50 and 90% repolarization at 0.5 and 1 Hz (P<0.05), while no prolongation occurred at 2 Hz. Voltage clamp experiments revealed a rapidly activating current, similar to current characteristics of canine atrial I(Kur), in approximately 70% of left ventricular myocytes. The IC(50) of 4-AP for this current was 24.2 microM. The concentration of 4-AP used in our experiments resulted in selective blockade of an outward current that was not I(to) or I(Kr). Beta-adrenergic stimulation with isoprenaline significantly increased the 4-AP sensitive outward current density (P<0.05), suggesting a role for this current during increased sympathetic stimulation. In silico incorporation into a canine ventricular cell model revealed selective AP prolongation after current blockade. CONCLUSIONS AND IMPLICATIONS: Our results support the existence of a canine ventricular plateau outward current sensitive to micromolar 4-AP and its constitutive role in ventricular repolarization.


Asunto(s)
4-Aminopiridina/farmacología , Canales de Potasio de Tipo Rectificador Tardío/efectos de los fármacos , Canales de Potasio de Tipo Rectificador Tardío/fisiología , Corazón/efectos de los fármacos , Bloqueadores de los Canales de Potasio/farmacología , Potenciales de Acción/efectos de los fármacos , Algoritmos , Animales , Simulación por Computador , Perros , Relación Dosis-Respuesta a Droga , Electrofisiología , Ventrículos Cardíacos/efectos de los fármacos , Técnicas In Vitro , Cadenas de Markov , Miocardio/citología , Miocardio/metabolismo , Miocitos Cardíacos/efectos de los fármacos , Técnicas de Placa-Clamp , Receptores Adrenérgicos beta/efectos de los fármacos , Receptores Adrenérgicos beta/fisiología , Soluciones
3.
Neural Comput ; 13(5): 1003-21, 2001 May.
Artículo en Inglés | MEDLINE | ID: mdl-11359642

RESUMEN

We study locally coupled networks of relaxation oscillators with excitatory connections and conduction delays and propose a mechanism for achieving zero phase-lag synchrony. Our mechanism is based on the observation that different rates of motion along different nullclines of the system can lead to synchrony in the presence of conduction delays. We analyze the system of two coupled oscillators and derive phase compression rates. This analysis indicates how to choose nullclines for individual relaxation oscillators in order to induce rapid synchrony. The numerical simulations demonstrate that our analytical results extend to locally coupled networks with conduction delays and that these networks can attain rapid synchrony with appropriately chosen nullclines and initial conditions. The robustness of the proposed mechanism is verified with respect to different nullclines, variations in parameter values, and initial conditions.


Asunto(s)
Encéfalo/fisiología , Simulación por Computador , Modelos Neurológicos , Conducción Nerviosa/fisiología , Neuronas/fisiología , Animales , Oscilometría , Tiempo de Reacción
4.
Am J Respir Crit Care Med ; 157(4 Pt 1): 1104-10, 1998 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-9563726

RESUMEN

Nitric oxide (NO) modulates pulmonary vascular resistance (PVR) in the normal fetus by increasing the cyclic guanosine 3',5'-monophosphate (cGMP) content of pulmonary vascular smooth muscle cells. Although several vasodilator stimuli, including acetylcholine, decrease fetal PVR through the release of endogenous NO, fetal pulmonary vasodilation is often transient despite prolonged treatment. Because cGMP is hydrolyzed and inactivated by cGMP-specific (type 5) phosphodiesterases (PDE5), we hypothesized that PDE5 activity contributes to high fetal PVR and limits the capability of the fetal pulmonary circulation to dilate or sustain vasodilation in response to cGMP-dependent stimuli. To test this hypothesis, we studied the hemodynamic effects of dipyridamole in 19 late-gestation fetal lambs. To determine whether dipyridamole-induced vasodilation is dependent upon basal NO release, we measured the response to dipyridamole before and after pretreatment with the NO synthase antagonist nitro-L-arginine (L-NA) in five fetal lambs. L-NA completely blocked dipyridamole-induced pulmonary vasodilation. To evaluate the effect of dipyridamole on pulmonary vasodilation due to the stimulated release of NO, we studied effects of prolonged intrapulmonary acetylcholine infusions, with and without concomitant administration of low-dose dipyridamole, in six fetal lambs. During prolonged (2-h) infusions, acetylcholine and dipyridamole individually caused transient pulmonary vasodilation. When administered together, pulmonary vasodilation was of greater magnitude and was sustained for the entire study period. To determine the effects of dipyridamole on endothelium-independent pulmonary vasodilation, we investigated the hemodynamic effects of inhaled NO (5 and 20 ppm) alone and in combination with dipyridamole during mechanical ventilation with low FlO2. The combination of dipyridamole with inhaled NO resulted in a greater degree of pulmonary vasodilation than that achieved with inhaled NO alone. We conclude that dipyridamole-induced pulmonary vasodilation is dependent on endogenous (basal) NO production and that dipyridamole potentiates vasodilator responses to endothelium-dependent and -independent dilators in the ovine fetal pulmonary circulation. We speculate that PDES activity opposes vasodilation and maintains high PVR in the normal fetal lung.


Asunto(s)
Acetilcolina/farmacología , Dipiridamol/farmacología , Feto/fisiología , Óxido Nítrico/farmacología , Circulación Pulmonar/efectos de los fármacos , Vasodilatación/efectos de los fármacos , Vasodilatadores/farmacología , Adenosina/farmacología , Animales , Aorta , Presión Sanguínea/efectos de los fármacos , Sinergismo Farmacológico , Endotelio Vascular/fisiología , Inhibidores Enzimáticos/farmacología , Óxido Nítrico Sintasa/farmacología , Nitroarginina/farmacología , Arteria Pulmonar , Ovinos , Resistencia Vascular/efectos de los fármacos
5.
Am J Physiol ; 271(6 Pt 2): H2638-45, 1996 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-8997326

RESUMEN

Although endogenous nitric oxide (NO) modulates basal tone in the fetal pulmonary and systemic circulations, little is known about its role in regulating ductus arteriosus (DA) tone. Immunostaining of DA tissue from late-gestation fetal lambs demonstrated strong staining for endothelial NO synthase (eNOS) in DA endothelium. To study the physiological role of the NO and guanosine 3',5'-cyclic monophosphate (cGMP) system in the DA in vivo, we measured the hemodynamic effects of NG-nitro-L-arginine (L-NNA; 30 mg), a NOS inhibitor, methylene blue (40 mg), a guanylate cyclase inhibitor, and indomethacin (0.8 mg), a cyclooxygenase inhibitor, in 10 chronically prepared late-gestation fetal lambs. L-NNA increased main pulmonary artery (MPA) and aortic pressures (P < 0.05 vs. baseline) but did not change the pressure gradient between the MPA and the aorta. L-NNA caused a small decrease in DA flow and a slight rise in resistance across the DA. Methylene blue increased both MPA pressure and the pressure gradient between the MPA and the aorta from 0.3 +/- 0.2 (baseline) to 7.0 +/- 2.7 mmHg (P < 0.05). Indomethacin increased both MPA pressure and the pressure gradient between the MPA and the aorta from 1.1 +/- 0.4 (baseline) to 6.3 +/- 1.5 mmHg (P < 0.05) after 40 min. Indomethacin decreased DA flow and increased DA resistance. We conclude that eNOS is in fetal DA endothelial cells and that NOS inhibition causes constriction of the DA in vivo. DA constriction after NOS inhibition is minimal, especially in comparison with cyclooxygenase inhibition. Methylene blue also constricts the DA, suggesting that guanylate cyclase activity contributes to DA relaxation. We speculate that, although the NO and cGMP system modulates DA tone, prostaglandins may play a greater role.


Asunto(s)
GMP Cíclico/fisiología , Conducto Arterial/fisiología , Feto/fisiología , Óxido Nítrico/fisiología , Animales , Inhibidores de la Ciclooxigenasa/farmacología , Conducto Arterial/efectos de los fármacos , Endotelio Vascular/embriología , Endotelio Vascular/enzimología , Inhibidores Enzimáticos/farmacología , Feto/metabolismo , Técnicas Inmunológicas , Indometacina/farmacología , Azul de Metileno/farmacología , Óxido Nítrico Sintasa/metabolismo , Nitroarginina/farmacología , Presión , Arteria Pulmonar/efectos de los fármacos , Arteria Pulmonar/embriología , Arteria Pulmonar/fisiología , Ovinos/embriología , Coloración y Etiquetado , Sistema Vasomotor/efectos de los fármacos
6.
Pediatr Res ; 39(3): 435-42, 1996 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-8929863

RESUMEN

Although endothelin (ET) contributes to the regulation of pulmonary vascular tone in the normal fetus, little is known about its role in pulmonary hypertension in the perinatal period. To examine the role of the ETB receptor in the normal ovine fetal lung, we studied the hemodynamic effects of ET-3 (a selective ETB receptor agonist) before and after RES-701 (a selective ETB receptor antagonist). RES-701 (10 mu g/min for 10 min) did not change basal pulmonary tone and blocked pulmonary vasodilation to ET-3 (500 ng/min for 10 min). To examine the effects of experimental perinatal pulmonary hypertension on activity of the ETA and ETB receptors, we studied the hemodynamic effects of ET-3, ET-1 (a nonselective ETA and ETB receptor agonist), and BQ 123 (a selective ETA receptor antagonist) in 12 chronically prepared late gestation fetal lambs after partial ligation of the ductus arteriosus. Serial changes in the pulmonary vascular effects of these agents were measured early (1-3 d) and late (7-10 d) after partial ductus arteriosus ligation. Left lung total pulmonary resistance in the normal late-gestation fetus was 0.62 +/- 0.01 mm Hg/ml/min (n = 4). After partial ductus arteriosus ligation, total pulmonary resistance increased to 1.2 +/- 0.3 (early; p < 0.05 versus normal), and progressively rose to 1.9 +/- 0.2 mm Hg/ml/min (late; p < 0.05 versus early). Intrapulmonary infusion of ET-3 (500 ng/min for 10 min) increased pulmonary blood flow from 94 +/- 11 to 183 +/- 17 mL/min in the normal fetus, but had no effect during late pulmonary hypertension. Infusions of ET-1 (50 ng/min for 30 min) caused transient pulmonary vasodilation followed by vasoconstriction during early pulmonary hypertension. During late pulmonary hypertension, however, infusion of ET-1 caused predominantly vasoconstriction. Pulmonary vasodilation to BQ 123 (100 mu g/min for 10 min) was greater during late than early pulmonary hypertension (43 versus 21%; p < 0.05). After 10 d of ductus arteriosus ligation, immunoreactive ET-1 content in whole lung tissue was 3-fold higher in hypertensive (n = 7) than control (n = 10) lungs (p < 0.05). We conclude that the ETB receptor contributes little to regulation of basal vascular tone in the normal ovine fetal lung and that chronic intrauterine pulmonary hypertension causes the loss of ETB-mediated vasodilation, progressive ETA-mediated vasoconstriction, and increased lung ET-1 content. We speculate that diminished ETB receptor-mediated vasodilation in combination with enhanced ETA receptor-mediated vasoconstriction and increased ET-1 production contributes to high pulmonary vascular resistance in perinatal pulmonary hypertension.


Asunto(s)
Endotelina-3/farmacología , Hipertensión Pulmonar/fisiopatología , Pulmón/fisiopatología , Receptores de Endotelina/metabolismo , Animales , Enfermedad Crónica , Conducto Arterial/efectos de los fármacos , Conducto Arterial/fisiopatología , Femenino , Hemodinámica , Ligadura , Pulmón/embriología , Péptidos Cíclicos/farmacología , Embarazo , Ovinos , Factores de Tiempo
7.
Am J Physiol ; 269(2 Pt 2): H473-9, 1995 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-7653611

RESUMEN

Endogenous nitric oxide (NO) modulates fetal pulmonary vascular tone by stimulating guanosine 3',5'-cyclic monophosphate (cGMP) production in vascular smooth muscle. Because cGMP is hydrolyzed and inactivated by phosphodiesterase enzymes, we evaluated the hemodynamic effects of two cGMP-specific phosphodiesterase (PDE5) inhibitors, dipyridamole and zaprinast, in the near-term chronically prepared ovine fetus. Brief (10 min) intrapulmonary infusions of dipyridamole caused dose-dependent increases in left pulmonary artery flow and decreases in left pulmonary arterial resistance that persisted for > 40 min after termination of the infusion. Prolonged (2 h) infusions of dipyridamole caused sustained pulmonary vasodilation throughout the infusion period. To compare the hemodynamic effects of dipyridamole with the PDE5 antagonist zaprinast, we studied the responses to equimolar doses of both agents in four fetuses. Zaprinast caused dose-dependent pulmonary vasodilation that was equivalent to that noted with equimolar doses of dipyridamole. To determine whether adenosine is involved with dipyridamole-induced pulmonary vasodilation, we compared the hemodynamic response to dipyridamole before and after administration of the potent adenosine receptor (P1) antagonist 8-phenyltheophylline (8-PT). Pretreatment with 8-PT markedly attenuated adenosine-induced pulmonary vasodilation but had no effect on the hemodynamic response to dipyridamole. We conclude that cGMP-specific phosphodiesterase activity is important in regulating fetal pulmonary vascular tone. In addition, dipyridamole administration causes dose-dependent pulmonary vasodilation that is equivalent to zaprinast and not primarily due to its effects on adenosine.(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
3',5'-GMP Cíclico Fosfodiesterasas/antagonistas & inhibidores , Dipiridamol/farmacología , Feto/fisiología , Arteria Pulmonar/embriología , Vasodilatación/efectos de los fármacos , Animales , Arteriolas/efectos de los fármacos , Arteriolas/embriología , Hemodinámica/efectos de los fármacos , Arteria Pulmonar/efectos de los fármacos , Antagonistas de Receptores Purinérgicos P1 , Purinonas/farmacología , Receptores Purinérgicos P1/efectos de los fármacos , Ovinos , Teofilina/análogos & derivados , Teofilina/farmacología , Factores de Tiempo , Resistencia Vascular
8.
Behav Modif ; 17(3): 339-66, 1993 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-8343102

RESUMEN

Generalization and social validity are necessary aspects of any applied behavior analytic endeavor. They are especially critical to social-skills training research and practice. Investigators have demonstrated the effectiveness of various learning theory-based interventions in teaching social skills to and increasing peer interactions of children with and without disabilities. However, development of a technology for reliably transferring these changes across different situations or ensuring their persistence over time has proven to be more problematic. From both a conceptual and empirical standpoint, this article reviews progress in and barriers to assessing and enhancing generality of social behavior change and its relationship to social validity. If progress is to be made, then it will be necessary to (a) distinguish between generalization and generality in developing and evaluating social-skills interventions; (b) expand the concept of social validity to give more emphasis to objective measurement of social skills, interventions, and outcomes; and (c) pursue a systematic analysis of generality- and durability-programming tactics.


Asunto(s)
Terapia Conductista , Trastornos de la Conducta Infantil/terapia , Conducta Social , Adolescente , Conducta del Adolescente , Niño , Preescolar , Femenino , Humanos , Masculino , Ajuste Social
9.
J Med Virol ; 37(2): 122-6, 1992 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-1629711

RESUMEN

The 2'-fluorinated arabinosyl-pyrimidine nucleosides, 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine (FIAC) and 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-methyluracil (FMAU), are new antiviral compounds with in vitro inhibitory activity against the DNA polymerase of hepadnaviruses. Those compounds also induced permanent inhibition of viral replication in woodchucks chronically infected by woodchuck hepatitis virus. The effects of these antiviral compounds were assessed in ducks chronically infected by duck hepatitis B virus (DHBV). Following intraperitoneal administration for 5 days, FMAU (2 mg/kg/day) and FIAC (10 mg/kg/day) induced a transient decrease in DHBV replication, as shown by the decrease in both the serum and liver DHBV DNA level. After stopping therapy, DHBV replication rebounded immediately to the pretreatment level. The supercoiled form of liver viral DNA was found to be less affected by the therapy. By contrast, no obvious antiviral effect was observed with vidarabine monophosphate (ara-AMP) (80 mg/kg/day) therapy. No sign of toxicity was observed during the course of the treatment. These preliminary results confirmed in the DHBV model the higher efficacy of FIAC and FMAU as compared to ara-AMP. Pharmacokinetic studies are needed to explain the differences observed in viral replication in these 2 models of HBV infection.


Asunto(s)
Arabinofuranosil Uracilo/análogos & derivados , Citarabina/análogos & derivados , Virus de la Hepatitis B del Pato/efectos de los fármacos , Hepatitis Viral Animal/tratamiento farmacológico , Animales , Antivirales/farmacología , Arabinofuranosil Uracilo/farmacología , Citarabina/farmacología , ADN Viral/sangre , ADN Viral/metabolismo , Evaluación Preclínica de Medicamentos , Patos , Virus de la Hepatitis B del Pato/aislamiento & purificación , Virus de la Hepatitis B del Pato/fisiología , Hepatitis Viral Animal/microbiología , Hígado/microbiología , Replicación Viral/efectos de los fármacos
10.
Cathet Cardiovasc Diagn ; 26(2): 127-9, 1992 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-1606601

RESUMEN

A 58-yr-old woman with a right atrial myxoma associated with a vascular malformation supplied by the right coronary artery is described. She presented with atypical chest pain that was reproduced during angiography of the malformation. Findings were confirmed during surgery.


Asunto(s)
Angiografía Coronaria , Anomalías de los Vasos Coronarios/diagnóstico , Atrios Cardíacos , Neoplasias Cardíacas/diagnóstico , Mixoma/diagnóstico , Ultrasonografía , Anomalías de los Vasos Coronarios/cirugía , Femenino , Atrios Cardíacos/patología , Atrios Cardíacos/cirugía , Neoplasias Cardíacas/irrigación sanguínea , Neoplasias Cardíacas/cirugía , Humanos , Persona de Mediana Edad , Mixoma/irrigación sanguínea , Mixoma/cirugía
11.
Antiviral Res ; 17(2): 157-67, 1992 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-1313221

RESUMEN

The nucleoside analog 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5- ethyluracil (FEAU) was tested in a rabbit model of acute herpetic keratitis and its effectiveness compared with that of acyclovir (ACV). FEAU or ACV was applied topically 3 times daily, beginning 3 days post-HSV-1 inoculation and continued for a period of 7 days. FEAU at a concentration of 1% (w/v) or 3% ACV resulted in significant lessening of the severity of corneal lesions, conjunctivitis, iritis, and corneal clouding at 24 to 48 h after beginning chemotherapy. No toxic reaction was observed in any rabbit eyes treated with either FEAU or ACV. The duration of virus shedding into tear film and colonization of the trigeminal ganglia, however, were not reduced by either FEAU or ACV treatment begun 3 days post-inoculation. Fifty percent effective dose (ED50) of FEAU determinations performed on isolates from tear film and on the virus inoculum in secondary rabbit kidney cultures yielded a range of 4.6-7 microM, with two in vitro resistant isolates having ED50S of greater than or equal to 1500 microM of FEAU. Fifty percent cell growth inhibition for FEAU was 3000 microM at 72 h.


Asunto(s)
Antivirales/uso terapéutico , Arabinofuranosil Uracilo/análogos & derivados , Queratitis Herpética/tratamiento farmacológico , Simplexvirus/efectos de los fármacos , Aciclovir/administración & dosificación , Aciclovir/farmacología , Aciclovir/uso terapéutico , Animales , Antivirales/administración & dosificación , Antivirales/farmacología , Arabinofuranosil Uracilo/administración & dosificación , Arabinofuranosil Uracilo/farmacología , Arabinofuranosil Uracilo/uso terapéutico , Células Cultivadas , Córnea/microbiología , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Queratitis Herpética/microbiología , Masculino , Soluciones Oftálmicas , Conejos , Simplexvirus/crecimiento & desarrollo , Simplexvirus/aislamiento & purificación
12.
J Med Chem ; 33(8): 2145-50, 1990 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-1695683

RESUMEN

1-(3-Azido-2,3-dideoxy-2-fluoro-beta-D-arabinofuranosyl)thymine (6, F-AZT) and 1-(2,3-dideoxy-2-fluoro-beta-D-threopentofuranosyl)cytosine (12, F-DDC) were synthesized from the potent antiherpes virus nucleosides 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)thymine (1, FMAU) and 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine (FIAC) in the hope that introduction of a 2-"up"-fluoro substituent might potentiate the anti-HIV activity of AZT and DDC. FMAU (1) was converted in three steps into 2,3'-anhydro-1-(2-fluoro-2-deoxy-5-O-trityl-beta-D-lyxofuranosyl)thymine (4), which when treated with NaN3 followed by detritylation afforded 6. F-DDC was prepared by two methods. Tritylation of FIAC followed by treatment of the product with thiocarbonyldimidazole afforded the 5'-O-trityl-3'-O-(imidazolyl)thiocarbonyl nucleoside 9. Upon radical reduction of 9 with Bu3SnH and AIBN, 5'-O-trityl-DDC 10 was obtained. Compound 10 was detritylated to give 12, which (when obtained by this procedure) resisted crystallization, but the diacetate 12' was obtained in crystalline form. Alternatively, FAC (14) was converted into N4,O5'-dibenzoyl derivative 15, which was treated with thiocarbonyldiimidazole. Reduction of 16 with Bu3SnH/AIBN followed by debenzoylation afforded 12, which was obtained in crystalline form. F-AZT did not exhibit any significant activity against the human immunodeficiency virus (HIV) in vitro. F-DDC, however, showed activity against HIV-1, but the therapeutic index is much inferior to that of AZT.


Asunto(s)
Antivirales/farmacología , VIH-1/efectos de los fármacos , Zalcitabina/análogos & derivados , Zidovudina/análogos & derivados , Antivirales/síntesis química , Línea Celular , Supervivencia Celular/efectos de los fármacos , Fenómenos Químicos , Química , Ensayo de Inmunoadsorción Enzimática , Técnica del Anticuerpo Fluorescente , Antígenos VIH/análisis , VIH-1/inmunología , Humanos , Estructura Molecular , ADN Polimerasa Dirigida por ARN/análisis , Zalcitabina/síntesis química , Zalcitabina/farmacología , Zidovudina/síntesis química , Zidovudina/farmacología
13.
Antiviral Res ; 13(4): 165-74, 1990 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-2166466

RESUMEN

1-(2-Deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-ethyluracil (FEAU) has been shown to be a highly effective inhibitor of Simian varicella virus infection in African green monkeys. Administration of FEAU by either intravenous injection or gavage at doses as low as 1 mg/kg/day prevented the development of rash and reduced viremia. The effective dose could be further reduced to 0.2 mg/kg/day when administered in combination with a sub-effective dose of human recombinant interferon-beta. No evidence of toxicity was seen in monkeys treated for 10 days with FEAU doses of 10 mg/kg/day when they were monitored by hematology and clinical chemistry tests and by clinical observations.


Asunto(s)
Infecciones por Adenoviridae/prevención & control , Antivirales/farmacología , Arabinofuranosil Uracilo/análogos & derivados , Interferón Tipo I/farmacología , Uridina/análogos & derivados , Adenovirus de los Simios/efectos de los fármacos , Animales , Arabinofuranosil Uracilo/administración & dosificación , Arabinofuranosil Uracilo/farmacología , Chlorocebus aethiops , Relación Dosis-Respuesta a Droga , Sinergismo Farmacológico , Humanos , Inyecciones Intravenosas , Interferón Tipo I/administración & dosificación , Proteínas Recombinantes , Viremia/tratamiento farmacológico
14.
Am J Hematol ; 33(4): 238-43, 1990 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-2316507

RESUMEN

Granulocyte transfusions are associated with a number of side effects including febrile transfusion reactions and occasionally pulmonary infiltrates. There is evidence that the presence of preformed antibodies may be a cause of these complications. In this study, allogeneic 111Indium-labeled granulocytes were used to evaluate the pulmonary retention of radioactivity in alloimmunized and non-alloimmunized patients in an attempt to assess antibody effect on granulocyte migration. After injection of labeled allogeneic granulocytes into neutropenic patients, the ratios of lung to heart activity were calculated for the first 30 min of scanning. There was significantly greater retention of radioactivity from cells in the lungs of patients who were alloimmunized, having both lymphocytotoxic (anti-HLA) and leuko-agglutinating antibodies, compared to the activity in the lungs of non-alloimmunized patients (P less than .001) or of patients receiving autologous granulocytes (P less than .001). This study demonstrates that labeled, mismatched granulocytes may be retained in the lungs for a significantly longer time in patients with preformed antibodies. This implies that transfusion of large numbers of such mismatched granulocytes, i.e., granulocyte transfusions, may also be retained in the lungs of alloimmunized patients, which could lead to pulmonary compromise. Therefore, granulocyte transfusions from random donors should not be given to alloimmunized patients.


Asunto(s)
Granulocitos/trasplante , Transfusión Sanguínea , Histocompatibilidad , Humanos , Inmunización , Radioisótopos de Indio , Isoanticuerpos/inmunología , Pulmón/inmunología
15.
Antimicrob Agents Chemother ; 34(3): 473-5, 1990 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-2334160

RESUMEN

The treatment of woodchuck hepatitis virus infections with 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine (FIAC) and 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-methyluracil (FMAU), given intraperitoneally, caused complete and permanent decrease of serum virus endogenous DNA polymerase and viral DNA in all treated woodchucks but was associated with severe toxicity. By contrast 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil (FEAU) induced a sustained, although less dramatic, decrease of viral replication without apparent toxic effect. FEAU was also effective when given orally. However, in both cases this inhibitory effect was transient.


Asunto(s)
Antivirales/farmacología , Arabinofuranosil Uracilo/análogos & derivados , Citarabina/análogos & derivados , Hepadnaviridae/efectos de los fármacos , Hepatitis Viral Animal/tratamiento farmacológico , Uridina/análogos & derivados , Replicación Viral/efectos de los fármacos , Administración Oral , Animales , Antivirales/administración & dosificación , Antivirales/uso terapéutico , Arabinofuranosil Uracilo/administración & dosificación , Arabinofuranosil Uracilo/farmacología , Arabinofuranosil Uracilo/uso terapéutico , Enfermedad Crónica , Citarabina/administración & dosificación , Citarabina/farmacología , Hepadnaviridae/fisiología , Hepatitis Viral Animal/microbiología
16.
Chem Pharm Bull (Tokyo) ; 37(2): 336-9, 1989 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-2743479

RESUMEN

Seven purine nucleosides containing the 2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl moiety were synthesized and tested for their antitumor activity. Direct condensation of 3-O-acetyl-5-O-benzoyl-2-deoxy-2-fluoro-D-arabinofuranosyl bromide (1) with N6-benzoyladenine in CH2Cl2 followed by saponification of the product afforded the adenine nucleoside (I, 2'-F-ara-A). Deamination of I with NaNO2 in HOAc gave the hypoxanthine analogue (II, 2'-F-ara-H). The 6-thiopurine nucleoside (III, 2'-F-ara-6MP) was prepared by condensation of 1 with 6-chloropurine by the mercury procedure followed by thiourea treatment and saponification of the product. Methylation of III gave the 6-SCH3 analogue (IV). Raney Ni desulfurization of III afforded the unsubstituted purine nucleoside (V, 2'-F-ara-P). Condensation of 1 with 2-acetamido-6-chloropurine by the silyl procedure afforded the protected 2-acetamido-6-chloropurine nucleoside which served as the precursor for both the guanine and 6-thioguanine nucleosides (VI, 2'-F-ara-G and VII, 2'-F-ara-TG, respectively). Thus, alkaline hydrolysis of the precursor gave VI. Thiourea treatment prior to alkaline hydrolysis gave VII. The new nucleoside, 2'-F-ara-G (VI) is found to be selectively toxic to human T-cell leukemia CCRF-CEM.


Asunto(s)
Arabinonucleósidos/síntesis química , Nucleósidos de Purina/síntesis química , Animales , Antineoplásicos/síntesis química , Antivirales/síntesis química , Arabinonucleósidos/farmacología , Fenómenos Químicos , Química , Humanos , Ratones , Nucleósidos de Purina/farmacología
17.
Antiviral Res ; 10(4-5): 153-66, 1988 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-2852483

RESUMEN

The incorporation and metabolism of 2'-fluoro-5-substituted arabinosyl pyrimidine analogs, and their selective inhibition of viral DNA synthesis in herpes simplex virus type 1 (HSV-1)-infected and mock-infected Vero cells were studied by HPLC and CsCl isopycnic density gradient analysis of isolated DNAs. The amounts of radiolabeled analogs incorporated as parent compound following 10 microM exposure for 4 h were 10-fold higher in HSV-1-infected vs mock-infected cells for 2'-fluoro-5-difluoromethyl-Ara-U (F2FMAU); 4.3-fold higher for 5-ethyl deoxyuridine (EdU); 2.6-fold higher for 2'-fluoro-5-methyl-Ara-U (FMAU) and 1.7-fold higher for dThd. For 2'-fluoro-5-ethyl-Ara-U (FEAU), 3.0 pmole of unchanged moiety was incorporated per 10(6) HSV-1-infected cells but no incorporation was detected in mock-infected cells. HPLC profiles showed that the percentages of radiolabeled analogs incorporated as parent compound in the DNA extracted from HSV-1-infected cells were 31.0% for F2FMAU, 99.6% for EdU, 83.5% for FEAU and 98.3% for FMAU; from mock-infected cells, they were 63.6% for F2FMAU, 96.7% for EdU, 97.3% for FMAU and no incorporation into DNA for FEAU was detected. CsCl density gradient analyses of isolated DNA showed that viral DNA synthesis was inhibited 98% by 10 microM FEAU, 92% by 10 microM F2FMAU, 90% by 2 microM FMAU and 80% by 50 microM EdU, whereas cellular DNA synthesis was inhibited by 53, 44, 61, 66 and 54%, respectively. We conclude that: (a) FEAU incorporation into host-cell DNA was not detectable but FEAU was selectively incorporated into HSV-infected cells; (b) FMAU and FEAU were metabolically stable; however, F2FMAU was extensively metabolized; (c) FEAU and F2FMAU were among the most selective inhibitors of HSV-1 DNA synthesis while allowing cellular DNA synthesis to continue.


Asunto(s)
Antivirales/farmacología , Arabinonucleósidos/farmacología , ADN Viral/biosíntesis , Nucleósidos de Pirimidina/farmacología , Simplexvirus/efectos de los fármacos , Animales , Antivirales/metabolismo , Arabinonucleósidos/metabolismo , Centrifugación Isopicnica , Cromatografía Líquida de Alta Presión , Estructura Molecular , Nucleósidos de Pirimidina/metabolismo , Simplexvirus/genética , Simplexvirus/metabolismo , Células Vero
18.
Res Dev Disabil ; 9(4): 359-76, 1988.
Artículo en Inglés | MEDLINE | ID: mdl-2462739

RESUMEN

We investigated the effects of group socialization procedures on the social behavior of preschool children in two studies. Group socialization procedures consisted of teachers using antecedent and consequent events to promote social interaction during children's games. During intervention, teachers discussed friendship with the children and then prompted and praised child-child social responding within the context of games. Children's social behavior was assessed during two sessions, group game periods (i.e., intervention sessions) and nonintervention play periods (i.e., generalization sessions). In both studies, a multiple baseline design across two target children and peers in their respective group was used to evaluate the effects of group socialization procedures. During group game periods, after intervention, target children increased their rates of both prompted and unprompted social interactions with peers. Also, in nonintervention play periods, target children improved both the rate and the duration of their social responding with peers. Results indicated that group socialization procedures were a practical and effective method for improving young children's social interaction during both structured games and unstructured play activities.


Asunto(s)
Discapacidades del Desarrollo/terapia , Educación Especial , Relaciones Interpersonales , Grupo Paritario , Socialización , Preescolar , Discapacidades del Desarrollo/psicología , Femenino , Procesos de Grupo , Humanos , Masculino , Juego e Implementos de Juego
19.
J Autism Dev Disord ; 17(3): 375-90, 1987 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-3654489

RESUMEN

A peer-initiation training procedure was implemented across multiple peer trainers to investigate social interactions between severely withdrawn autistic children and their nonhandicapped peers. For one subject, substantial increases in spontaneous interactions with training and nontraining peers occurred after the peer-initiation procedure was applied across two training exemplars. Spontaneous social interactions continued even after the training procedure was removed. Although experimental control was established with the second subject during training, spontaneous interactions during nontraining periods were primarily with training peers. The results contribute to an emerging data base on the social interactions of autistic and severely withdrawn handicapped children and on peer-initiation training procedures.


Asunto(s)
Trastorno Autístico/psicología , Educación de las Personas con Discapacidad Intelectual , Conducta Social , Niño , Femenino , Humanos , Masculino , Grupo Paritario
20.
Antimicrob Agents Chemother ; 31(9): 1355-8, 1987 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-2823696

RESUMEN

2'-Fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil (FEAU) was synthesized, and its biological activities were compared with those of 2'-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (FMAU). Earlier studies indicated that both compounds showed potent anti-herpes simplex virus activity, with a 50% effective dose (ED50) of less than 0.25 microM. In the present study the cell growth inhibitory activity of FEAU (ED50, 200 to 2,060 microM) was found to be about 100-fold less than that of FMAU. With an ED50 ranging from 630 to 3,700 microM, FEAU only weakly inhibited thymidine incorporation into DNA, as compared with FMAU with an ED50 of 9 to 28 microM. Following exposure to [2-14C]FEAU (100 microM), 0.48 pmol/10(6) cells per h was incorporated into the DNA of herpes simplex virus type 1-infected Vero cells, whereas no detectable incorporation was found in uninfected Vero cells or L1210 cells. The Ki of FEAU for thymidine kinase purified from human leukemic cells was greater than 150 microM. For herpes simplex virus type 1- and 2-encoded thymidine kinases, the Kis were 0.6 and 0.74 microM, respectively. Both FEAU and FMAU were relatively nontoxic for mice, with a 50% lethal dose of greater than 800 mg/kg per day (four intraperitoneal doses). However, the lethal dose of FEAU for dogs was 100 mg/kg per day (10 intravenous doses), a dose which is 40- to 80-fold greater than the toxic dose of FMAU. These results suggest that FEAU is a worthy candidate for further development as an antiherpetic agent.


Asunto(s)
Antivirales , Arabinofuranosil Uracilo/análogos & derivados , Arabinofuranosil Uracilo/toxicidad , Uridina/análogos & derivados , Arabinofuranosil Uracilo/síntesis química , Línea Celular , Supervivencia Celular/efectos de los fármacos , ADN/biosíntesis , Simplexvirus/enzimología , Relación Estructura-Actividad , Timidina Quinasa/antagonistas & inhibidores
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...